

# Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review

Ketevan Pachkoria<sup>\*1</sup>, M<sup>a</sup> Isabel Lucena<sup>1</sup>, Mariam Molokhia<sup>2</sup>, Raquel Cueto<sup>1</sup>, Alfonso Serrano Carballo<sup>3</sup>, Alfonso Carvajal<sup>4</sup> and Raúl J. Andrade<sup>4</sup>

<sup>1</sup>Clinical Pharmacology Service and <sup>4</sup>Liver Unit, University Hospital Virgen de la Victoria, School of Medicine, Málaga, Spain; <sup>2</sup>Department of Epidemiology & Population Health London School of Hygiene & Tropical Medicine, <sup>3</sup>Servicio de Inmunología, Hospital Virgen de la Victoria, Málaga, Spain; <sup>4</sup>Instituto de Farmacoepidemiología de la Universidad de Valladolid, Spain

**Abstract:** The diagnosis of drug-induced liver injury (DILI) is challenging and based on complex diagnostic criteria. DILI falls into two main categories i) intrinsic “dose-dependent” Type A reactions ii) “idiosyncratic” or Type B reactions (which are usually not predictable). Idiosyncratic reactions can be immunoallergic (hypersensitivity), or metabolic, although overlap between categories can occur. The aim of this review is to summarise the general view of underlying mechanisms in DILI and to highlight individual risk factors for developing hepatotoxicity. Polymorphisms of bioactivation/toxification pathways through CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III) are explored together with immunological factors in hepatotoxicity. The importance of establishing a multidisciplinary and multicentric network to promote the understanding and research in hepatotoxicity is underlined. Challenges such as genetic analyses for association studies and whole genome studies, pharmacogenetic testing and future approaches to study DILI are considered. Knowledge regarding these operational mechanisms could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity.

**Keywords:** Drug-induced liver injury (DILI), molecular mechanism of DILI, genetic polymorphism, Phase I, II and III enzymes, genetic testing.

## 1. GENERAL OVERVIEW OF DILI

DILI is a challenge in modern pharmacology and remains the single leading cause of drug withdrawal despite of a rigorous preclinical and clinical review process [1-3]. DILI has been linked to nearly one thousand drugs used in clinical practice [4] and it also nowadays accounts for more than 50% of the cases of acute liver failure in the USA [2].

The main drug classes associated with DILI are: antibacterial agents, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics [5, 6], perhaps because they represent the most commonly prescribed drugs. Although data to accurately estimate occurrence of DILI are lacking, the frequency of unpredictable hepatotoxicity associated with the use of medication is suggested to be around 1 per 10, 000 to 1 per 100,000 exposed individuals [7, 8].

In addition, the incidence of DILI remains largely underestimated in general population because of under-reporting, difficulties in diagnosis, variation of the clinical setting and incomplete examination of exposed individuals. In a French general population, the frequency of DILI was estimated to be about 14 per 100.000 inhabitants per year [9]. Besides this, a recent study suggests that 1% of medical inpatients develop DILI during the course of hospitalization [10]. One of the major challenges on DILI is to understand the environmental and genetic factors that are operating and to identify individual susceptibility to idiosyncratic liver injury. The

present review examines current concepts of molecular mechanism related to the pathogenesis of hepatotoxicity.

## 2. GENETIC MECHANISMS OF DILI

The general view on the pathogenesis of DILI is that parent compounds are rendered hepatotoxic during cytochrome (CYP) 450 metabolism and can exert their action within the target cell [11], although other metabolic pathways can contribute. However, data on CYP polymorphism in DILI are lacking apart from anecdotal reports. Below we will discuss the impact of Phase I, II and III enzymes polymorphism and susceptibility to develop DILI.

### Phase I, II, III Reactions

Drug metabolism encompasses three Phases: Phase I, or bioactivation/toxification reactions through CYP450 enzymes, Phase II, or detoxification reactions (synthetic conjugations with glucuronic acid, sulfate, glutathione, acetate, and amino acids) and Phase III (excretion/transport). During toxification (Phase I) reactions, introduction of functional group (-OH, -NH<sub>2</sub>, -SH or -COOH) take place thus making the chemical compound more water soluble. Indeed, water-solubility of chemical compound further continues in detoxification (Phase II). Ultimately, hydrophilic drug metabolites may be exported by Phase III proteins located at the hepatocyte or cholangiocyte apical canalicular membrane (MRP family, MDR) that shift chemical compounds into the sinusoidal circulation or bile. Slight imbalance of Phase I, II and III Phases might have important chemical consequences, leading to covalent binding, lipid peroxidation, oxidative stress or glutathione depletion. Polymorphic microsomal enzymes appear to play a role in hepatotoxicity with various compounds.

\*Address correspondence to this author at the Unidad de Hepatología, Departamento de Medicina, Facultad de Medicina, Boulevard Louis Pasteur, 32, 29071-Málaga, Spain; Tel: +34 952 134242; Fax: +34 952 131511; E-mail: andrade@uma.es

### Phase I Enzymes

Cytochrome P-450 is a key enzyme of Phase I metabolism representing the major pathway for drug oxidation. Approximately fourteen CYP families have been described in humans, genetic polymorphism affecting CYP2C9, CYP2C19 and CYP2D6 genes, rendering them relevant to drug metabolism and possibly hepatotoxicity [12-17]. Indeed, several factors such as genetic (SNP, gene duplication) and environmental (drug interactions, underlying disease) are suggested to affect the level and activity of CYP-450 thus leading to altered drug metabolism and formation of toxic metabolites [18]. Furthermore, marked differences regarding CYP isoenzymes have been found between ethnic groups [19-21]. The ethnic difference between certain isoenzymes may determine differences in drug response across populations, therefore ethnicity would give additional information to clinicians for prospective evaluation of patients at risk.

### CYP2C9 and Hepatotoxicity

CYP2C9 is the most abundant among human CYP2C isoform, representing 18% of total hepatic CYPs [22]. This enzyme metabolizes a number of therapeutically important drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), S-warfarin, phenytoin and losartan [19]. Flucanazol, metronidazol and amiodarone are potent inhibitors of this enzyme, while barbiturate and phenytoin coadministration may induce the CYP2C9 activity. To date, three different allelic variants (CYP2C9\*1,\*2,\*3), has been recognized to be functionally important [19]. In particular, \*3 allele, appears to confer the largest reduction in metabolic activity *in vitro* and clinically significant alterations in the pharmacokinetics of CYP2C9 substrates [20, 22] while the \*2 allele produces intermediate reduction in enzyme activity, as compared to wild type \*1 [22]. The frequencies of defective alleles CYP2C9\*2 and CYP2C9\*3 vary between 8-12% and 3-8%, respectively, among Caucasians, while they are lower in Orientals and black Africans [19, 20].

Drugs being substrate for CYP2C9 isoforms are known to be hepatotoxic. However, it is not yet known whether variation in CYP2C9 enzyme activity might play a role in determining or predicting risk of hepatotoxicity. To our knowledge only single case reports suggest possible implication of CYP2C9 genotype in DILI [22, 23]. A case of leflunomide-induced severe hepatotoxicity was implicated to a rare CYP2C9\*3/\*3 genotype [24]. Furthermore, CYP2C9 is known to mediate biotransformation of most non steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac, ibuprofen, indomethacin, naproxen and Cox-2 inhibitors by methyl-hydroxylation. Based on clinical reports, CYP2C9 was thought to be a promising probe candidate for diclofenac hepatotoxicity [25]. However, the pharmacokinetics of diclofenac was found to be independent of CYP2C9 polymorphism [22, 26, 27]. Altered expression of alternative cytochromes (e.g., CYP2C8) [28] and cytokines (IL-4, IL-10) [29] was suggested to be determinant of diclofenac hepatotoxicity. Besides, CYP2C9 is known to mediate biotransformation of HMG-CoA reductase inhibitors such as fluvastatin to toxic metabolites 5-hydroxy-, 6-hydroxy-, and *N*-deisopropyl-fluvastatin, although the presence of variant genotype did not show to have any influence on fluvastatin kinetics and appearance of adverse drug effect [30].

### CYP2C19 and Hepatotoxicity

The deficiency of CYP2C19 is responsible for the genetic polymorphism of S-mephenytoin 4-hydroxylation [31]. Many therapeutically used drugs such as omeprazole, diazepam, propranolol, labetalol, nelutamide, tienilic acid, glucocorticosteroids, sexual steroids, ketoconazole and warfarin are subject of S-mephenytoin oxidation [32-35]. Two major mutation in CYP2C19 gene has been identified: CYP2C19\*2 has a single pair mutation, producing aberrant splice site in Exon 5 resulting in modification of a reading frame and forming a premature stop codon, and CYP2C19\*3 consisting in a G→A mutation at position G36 of Exon 4 of CYP2C19 creating a stop codon [36]. It is noteworthy, that CYP2C19\*2 mutation account for 75% of the alleles in Orientals [36] and 95% in Caucasians [37] while the CYP2C19\*3 accounts for 25% of the alleles in Oriental poor metabolizers only and is not detected in Caucasians [38].

The role of CYP2C19 variant genotype on DILI appearance has not been well established. Study of Horsmans Y *et al.* suggested that Atrium<sup>®</sup> (a complex of phenobarbital and derivative of carbamates (febarbamate and difebarabmate) [39] (already removed from the market) induced hepatotoxicity might be associated with the deficiency of S-mephenytoin although the need of further confirmation was highlighted. Indeed, two out of three patients with Atrium<sup>®</sup>-induced hepatitis were found to have a deficient phenotype while the third one exhibited intermediate oxidation capacity. A case of severe troglitazone hepatotoxicity (withdrawn from the market) [12] was described in a carrier of partial or complete deficiency of CYP2C19 genotype. However these studies have not been replicated to date.

In sum, the relevance of CYP2C9 and CYP2C19 polymorphism on the development of DILI has been based on single studies, or small number of patients. In the series of DILI cases (n=60), prospectively collected, the distribution of CYP2C9 (n=28) and CYP2C19 (n=32) allelic variants in DILI patients were similar to those in other European populations, and there were no patients exhibiting very low enzyme activity for CYP2C9 \*3/\*3 and CYP2C19 \*3/\*3 alleles. Patients with variant and those with wild-type allele did not differ in regard to clinical presentation of DILI, type of injury and outcome. This data suggest that CYP2C9 and CYP2C19 genetic polymorphisms might not be a predictable potential risk factor for DILI [40].

### CYP2D6 and Hepatotoxicity

CYP2D6 represents an average of 2% of hepatic CYP content. The CYP2D6 is responsible for the debrisoquine/dextromethorphan oxidation which exhibit genetic polymorphism [41]. Approximately 40 therapeutically utilized drugs are oxidized by CYP2D6 including b-blockers, tricyclic antidepressants, selective serotonin re-uptake inhibitors (SSRI), antipsychotic, anti-arrhythmic and opioids (codeine, tramadol, dextromethorphan) [42]. Contrary to all other CYPs involved in drug metabolism, CYP2D6 is not inducible. Of note, approximately 3-10% of Caucasians are poor metabolizers compared with 1-2% of Orientals [43]. CYP2D6 deficiency largely contributed to perhexiline hepatotoxicity suggesting that perhexiline may accumulate in hepatocytes, which could lead to phospholipidosis and alcohol-like liver disease [44]. Also a study by Watson RGP *et*

al, showed a very high oxidation capacity in subjects with chlorpromazine induced hepatitis [45].

Seybold U *et al.* reported the first case of senna causing hepatitis at a low dose in a 28-year-old woman with known homozygosity for the CYP2D6 variant [17]. Furthermore, Maurer HH *et al.* suggested that the possible hepatotoxic effects of “designer drugs” including amphetamine derivatives, piperazine drugs and pyrrolidinophenones might be due to CYP2D6 polymorphism [46]. Several reports of hepatotoxicity recorded were due to anti-depressant drugs that are substrate of CYP2D6 enzyme [47, 48]. For mianserin hepatotoxicity, an immunologically-mediated mechanism has been proposed. Mianserin is converted by microsomes (CYP2D6) into a reactive metabolite, desmethylmianserin, which exhibits cytotoxicity [47]. However, routine monitoring of concentrations of the parent drug or the demethylated metabolite is not useful since liver injury has not been related to the plasma concentrations of these compounds, although in certain cases, improvement was achieved after a dose reduction [48].

Trazodone hepatotoxicity is related to its toxic metabolite m-chloro,4-phenylpiperazine (mCPP) generated by CYP3A3/4 dependent. Subsequent mCPP metabolism is mediated by CYP2D6, which shows genetic polymorphism. Therefore, steady-state concentrations of mCPP are markedly higher in poor metabolisers than in extensive metabolisers [47]. Inhibition of trazodone metabolism mediated by thioridazine (a CYP2D6 inhibitor) in humans produced an increase in the plasma concentrations of mCPP of 50% [49]. In fact, the combination of trazodone and trifluoperazine (a neuroleptic drug) was used in the only case reported as leading to fatal liver failure [50].

### CYP3A and Hepatotoxicity

The human CYP3A subfamily consists of 3 isoforms, 3A4, 3A5 and 3A7, encoded by gene located in the chromosome 7 [51]. This isoform catalyzes the biotransformation of a large number of structurally diverse and endogenous compounds [52]. CYP3A4 drug metabolizing activity has been reported to vary more than 20-fold among individuals and plays important roles in the metabolism of a wide variety of drugs, such as immunosuppressants, calcium channel blockers, cancer chemotherapeutic agents, antihistamines, sedatives, and synthetic estrogens [53]. CYP3A4 is the most abundant isoform in the human liver, accounting for approximately 30% of total CYP liver contents and for the majority of CYPs in the human small bowel [54]. According to experimental and clinical data, CYP3A4 induction occurs in acute cholestasis and/or elevated concentration of secondary bile acids *via* the pregnane X receptor (PXR) [55, 56]. Moreover CYP3A has been reported to play a major role in ethanol-mediated increases in acetaminophen hepatotoxicity [57].

Several therapeutic drugs used in clinical practice are catalyzed selectively by CYP3A4 enzyme. Therefore generation of reactive metabolites through CYP3A4 mediated metabolism might contribute to the drug induced liver injury such as flucloxacillin induced cholangiopathies [58], trioleandomycin induced cholestasis [59] and troglitazone induced liver injury [60]. Recently severe hepatotoxicity due to unfavourable interaction between amiodarone-simvastatin

[61] and raloxifene-fenofibrate [62] were possibly related to CYP3A4 inhibition.

### Phase II Enzymes

Phase II enzymes are involved in conjugation of various Phase I compounds or in direct metabolic activation. Compared to Phase I, phase II reaction generally proceed faster resulting in increase drug water-solubility [63]. Several hepatic non enzymatic and enzymatic pathways of detoxification have been identified, including glutathione conjugation of quinones by glutathione S-transferases (GSTs) and hydration of arena oxides to dihydrodiols by epoxide hydrolases [63]. However, reactive metabolites may not undergo detoxification, either because they are poor substrates or because of failure of detoxification enzyme function (genetic polymorphism) [64]. Phase II enzymes are known to be polymorphically expressed. The major Phase II enzymes implicate in hepatotoxicity are N-acetyltransferase 2 (NAT2), the glutathione M and T (GSMT and GSTT) and the thiopurine S-methyltransferase (TPMT) (Table 2).

### N-Acetylation and Hepatotoxicity

The N-acetylation is controlled by a pair of allele at a single gene locus. The frequency of rapid acetylators is 70% in Asians while in Western Europe and North America ranges from 30 to 60% [65, 66]. Many therapeutically used drugs such as isoniazid, sulfonamides, procainamide, hydralazine, dapsone, phenelzine, acebutolol and caffeine are substrates of N-acetylation [67]. Adverse clinical reactions have been related to the presence of N-acetylation polymorphism [68].

N-acetylation polymorphism is due to genetic deficiency of N-acetyltransferase 2 (NAT2) activity. In human populations, 27 alleles have been reported for NAT2. Of these, allele \*5, \*6, \*7 are of main importance exhibiting marked differences in metabolic activity of NAT2. The gene frequency of \*5, \*6, and \*7 are about 44.2%, 25.6%, and 1.2%, respectively, in Caucasians [69, 70] and 6.0%, 30.5%, and 11.2%, respectively, in Chinese [71]. Subjects who carry two defective NAT2 alleles exhibit slow acetylator capacity, whereas rapid acetylators are homozygous or heterozygous for wild-type NAT2.

An association between slow N-acetylation and sulfonamides hepatotoxicity leading to enhanced production of chemically reactive metabolites such as hydroxylamines, has been described [23]. Moreover, the risk of hepatotoxicity might be enhanced in patients with poor N-acetylation capacity as suggested for dihydralazine [72-74]. Regular monitoring of serum aminotransferase was suggested in slow NAT-2 acetylators receiving isoniazid treatment [72]. Isoniazid is metabolized to acetylisoniazid *via* hepatic N-acetyltransferase (NAT) [75]. Further acetylisoniazid is hydrolysed to acetylhydrazin, that is oxidised by CYP2E1, forming hepatotoxic intermediates [75, 76]. However acetylhydrazin is further acetylated by NAT into non-toxic metabolite, diacetylhydrazin [73, 74].

The current view of predisposition to hepatotoxicity is that acetylation of the moiety to a non-toxic derivate is impaired in slow acetylators thus favouring alternative CYP450 mediated pathway to form a toxic-metabolite. Thus slow acetylators might develop severe hepatotoxicity as it was a

case for isoniazid-induced liver injury [72] compared to a rapid acetylators.

### **Sulfoxidation and Hepatotoxicity**

Sulfoxidation polymorphism has been implicated in chlorpromazine hepatitis [45]. Chlorpromazine induced hepatotoxicity has been strongly correlated with sulfoxidation deficient phenotype [45]. Hypothetically, larger fraction of the drug in sulfoxidation deficient subjects undergoes biotransformation through the alternative pathway of CYP450 system leading to reactive metabolite formation thus provoking immunoallergic hepatitis. Moreover, primary biliary cirrhosis has been described to be associated with sulfoxidation deficiency [77]. Other examples where the reactive metabolite was thought to be responsible for idiosyncratic reactions through deficiency of epoxide hydrolase has been reported in the case of the anticonvulsants, although this hypothesis has been recently placed in doubt [78].

### **Phase III Enzymes**

Under physiological conditions, hepatocyte actively converts all exogenous and endogenous substances into anionic conjugates with glutathione, glucuronate, sulfate, or other negatively charged molecules that lead to drug detoxification [8, 79]. Thus, these chemical substances formed by drug detoxification may become substrate for export pump of the multidrug resistance protein (MRP) family that mediated ATP dependent secretion across the canalicular membrane into the bile [80] and multidrug resistance 3 gene (MDR3) [81].

### **MRP Family and Hepatotoxicity**

In humans, the best characterized members of the MRP family are MRP1 and MRP2, which share similar substrate specificity [82]. MRP 1 gene is located on chromosome 16 [83] and MRP2 gene is located on chromosome 10 [84, 85]. Genetic predisposition represented by nonsense or missense (including amino acid polymorphism) MRP family mutations could manifest under the pressure of xenobiotic intake.

MRP1 is localized generally in the basolateral hepatocyte membrane [86]. High affinity substrates for MRP1 are: mono/bis glucuronosyl bilirubin, endogenous glutathione S-conjugate leukotriene C<sub>4</sub>, 17 $\beta$ -glucuronosyl estradiol [87]. Much lower affinity exhibit the following substrates: glutathione S-conjugates, sulfoconjugates, glucuronides of drugs and other xenobiotics. MRP and its related transporters (Pgp) has been reported to play an important physiologic role in defending the cellular environment from the endo- and/or xenobiotic toxins [88]. MRP2 is expressed in the apical (canalicular membrane) of hepatocytes. Inhibitor of MRP2 include cyclosporine A [89]. Consequently, xenobiotics that inhibit conjugation export pump could induce cholestasis in susceptible individuals. Indeed, the cholestatic type of liver injury produced by sulindac, flucloxacillin and terbinafine is attributable to its inhibition of canalicular bile salt transport [58, 90, 91]. Besides, Mrp-2 deficient rats do not develop cholestasis after the exposure of bile ductular toxins [92].

### **MDR3 and Hepatotoxicity**

Recently, the role of multidrug resistance 3 gene (MDR3) in developing drug-induced cholestasis was discussed [81].

MDR3 gene is located on chromosome 7 and belongs to ATP-binding cassette transporters [93]. These transporters are generally expressed in the canalicular membrane of the hepatocytes. It has been reported, that heterozygosity of MDR 3 gene lead to defective protein trafficking [94] and susceptibility to cholestasis of pregnancy [95] as well as genetic predisposition to certain biliary diseases [95-97]. It is thought that non genetic factors, such as female sex or reactive metabolites may also modify MDR 3 heterozygous state expressivity by decreasing normal allele expression [95] thereby altering drug transport. However, only limited information of Phase III proteins and the role in predicting risk of hepatotoxicity is available.

### **3. IMMUNOLOGICAL MECHANISMS**


Individual susceptibility to idiosyncratic hepatotoxicity is a complex and multi-step process determined by the interaction of multiple metabolic pathways as well as immunological factors that might influence immune responsiveness and tissue injury. Furthermore we will discuss a possible contribution of immunological factors such as genetic variations of human leukocyte antigen (HLA) molecules and inflammatory cytokines in the appearance of immunoallergic drug hepatotoxicity.

#### **Mechanism of Immune-Mediated Idiosyncratic Liver Injury**

Generally, immune mediated hepatotoxicity appears to involve the generation of reactive metabolites that undergo covalent binding with hepatocytes/carrier proteins, also known as "haptization" [79], however the pattern of the immune response to adduct is likely to vary among individuals [98, 99]. Besides it is not yet clear whether the association of immune mediates liver injury and reactive metabolite formation are coincidental or consequential.

Hapten formation leading to major histocompatibility complex class II (MHC II) presentation of haptenized peptides by antigen-presenting cells (APCs) along with costimulation of APC by "danger" signals promote helper T-cell activation (clonal antigen-recognizing cytotoxic cell expansion) and B-cell mediated antibody production. In response to cellular stress/death signal, innate immune system leads to the production of protective and/or injurious cytokines [100]. Such a "danger" signals may occur as a consequence of toxic drug metabolites, viral infections or systemic inflammatory conditions. This may explain why AIDS patients more frequently develop immune mediated liver injury (cytokine imbalance) [101].

Therefore, modulating of innate immune response might be crucial in the determining severity and extent of liver injury (Fig. 1). Consequently, factors affecting expression of protective cytokines (genetic polymorphisms) or an underlying disease might favour liver toxicity. The balance between protective (Interleukine (IL)-10, IL-6, monocyte chemoattractant protein (MCP)-1, MCP-2) and pro-inflammatory cytokines (Interferon (IFN)- $\gamma$ , Fas ligand (FasL), Tumor-necrosis factor (TNF) in the liver has been suggested to determine the extent of organ damage and the mode of cell death (apoptosis and necrosis) [79]. Studies in IL-10 knock-out mice reported that IL-10 is protective in APAP toxicity by controlling NO and iNOS formation [102]. Furthermore,



**Fig. (1).** Role of innate immune response in bile duct injury.

We might hypothesize that haptenization of toxic intermediates in the canalicule may trigger an immune response directed against bile duct epithelial cells. Cholangiocytes after this inflammatory insult become activated and enhance expression of DRB1\*15 and DQB1\*16 alleles. The HLA-restricted presentation of immunogenic peptides to helper T-cell that are activated leading to T-cell responses and amplification of the immune response, the cytotoxic T cells (would recognize the drug-protein epitopes presented by HLA class I molecule on the hepatocyte surface) or antibody producing B cells that would generate antibody to haptenized protein or autoantibodies. Abbreviation: TC, T cytotoxic cell; TH, T helper; HLA, human leukocyte antigen, IL, interleukin; INF, interferon.

knockout mice of IL-10 and IL-6 was demonstrated to be associated with increased susceptibility to paracetamol hepatotoxicity [103] and increased levels of TNF- $\alpha$  and IFN- $\gamma$  [104]. According to the results of small study an association between IL-10 and IL-4 polymorphism and diclofenac hepatotoxicity was also found [29]. Thus, it may be that proinflammatory cytokines contribute to the toxicity, and that they are regulated by anti-inflammatory cytokines, such as IL-10 and others. Interestingly, the analysis of three polymorphisms -1082G/A, -819C/T, and -592C/A in the IL-10 gene promoter were performed in a cohort of 146 DILI patients. In this exploratory study no association between IL-10 polymorphism and the development of DILI was found [105].

#### HLA Genotype and Idiosyncratic Drug-Induced Liver Injury


Major histocompatibility complex molecules (i.e. class I and II HLA molecules) participate in antigen presentation to immunocompetent cells and in the regulation of the immune response. An association of particular HLA molecule with the susceptibility to suffer liver injury from several immunogenic drugs has been reported using serological studies. For example, HLA-A11 in hepatitis induced by halothane, amineptin, amitriptyline and diclofenac, HLA-B8 in clometacin hepatitis, HLA-DR6 and DR2 in nitrofurantoin and chlorpromazine hepatitis [12]. All these studies, however, were small and hence the associations have become inconclusive. Additional immunological determinants in predisposing

DILI are given in the Table 3. Significant association was found between DRB1\*1501-DRB5\*0101-DQB1\*0602 haplotype and cholestatic hepatitis related to amoxicillin-clavulanate [106] and DRB1\*0201-associated DRB1\*0301, DRB1\*0701 haplotype and cytotoxic hepatitis related to antituberculous therapy [107]. Conversely, when using serological methods no association was found between general propensity to DILI (regardless to causative drug) and HLA class I and II molecule in a large group of patients (n=71) [108]. In a recent study using genomic techniques to assess HLA-class II molecules in the largest cohort of DILI patients analysed to date (n=140) [109], no association between any specific HLA allele and the propensity to develop DILI was demonstrated. In this study, on the other hand, a significant association between HLA-DRB1\*15 and -DQB1\*06 alleles and cholestatic/mixed pattern of DILI was found while DRB1\*07 and DQB1\*02 alleles appeared to be protective from this particular expression of liver injury. These findings suggest that HLA class II allele may explain in part why a given drug provokes different types of liver damage among patients, and also supports the general notion on the allergic based mechanism of cholestatic/mixed hepatotoxicity.

#### 4. MOLECULAR MECHANISM

##### Mechanism of Apoptosis and Necrosis

Hepatocyte death normally follows one of two patterns: necrosis or apoptosis (Fig. 2).



**Fig. (2).** Molecular mechanisms involved in DILI.

Abbreviations: ER-endoplasmic reticulum; NK, natural killer.

However, apoptosis and necrosis are usually consequence of the same initiating factors and signaling pathways [110]. It is currently not known, which mode of cell death predominates in various type of liver injury.

Apoptosis is a programmed cell death often initiated by specific stimuli, including DNA damage (ionizing radiation or chemotherapy) and death receptor ligands (TNF $\alpha$ , Fas ligand) [111]. These events lead to an increased leakage of proapoptotic cytochrome c, Smac/Diablo, etc [112] from the mitochondrial intermembrane space into the cytosol, thereby carrying out the cellular disassembly. Apoptosis leads to an individual cell resorption and distinctive nuclear changes (chromatin condensation, nuclear fragmentation and internuclear DNA degradation) and ultimately, Councilman (apoptotic) body's formation subjected to phagocytosis by adjacent cells and macrophages. On the other hand, necrosis is a consequence of acute metabolic perturbation leading to severe ATP depletion, irreversible breakdown of plasma membrane barrier, mitochondrial depolarization, lysosomal breakdown, collapse of electrical gradient and leakage of cytosolic compounds and reactive metabolites [113]. Membrane blebbing due to ATP depletion-dependent cytoskeleton alteration is an essential characteristic of necrosis [114, 115], while loss of membrane integrity is a typical sign distinguishing apoptosis from necrosis [116].

### Modulators of Apoptosis

The disassembly process in apoptosis is executed by ATP dependent death ligand/death receptor interaction, which leads to caspase (cysteine-dependent aspartate specific proteases) activation cascade. The activation of caspase cascade is orchestrated by two types of signals: caspase initiators (caspases 8 and 9) and caspase terminators (caspases 3, 6 and 7) that execute cell to apoptosis. The signal of caspase initiators converge to produce mitochondrial permeabilization by activating proapoptotic Bcl2 family members (tBid, Bax, Bak) that might form specific cytochrome c release channels in the mitochondrial outer membrane [111, 117] and/or mitochondrial permeability transition (MPT) pores in the inner mitochondrial membrane. Consequently opening of these pores leads to mitochondrial swelling and release of intermembrane proteins (cytochrome c, Smac, poly(ADP-ribose) polymerase (PARP) and other apoptosis inducing factors) [118]. Once cytochrome c is released, it activates the sequence caspase 9 in ATP-requiring reaction that in turn activates caspase 3 and the final stage of apoptosis.

Acetaminophen (APAP) is a powerful inducer of oxidative stress, DNA fragmentation, and apoptosis. The C-jun (NH<sub>2</sub>) terminal kinase (JNK) signal transduction pathway was suggested to be involved in the pathogenesis of paracetamol induced liver failure [121, 122]. C-jun (NH<sub>2</sub>) terminal kinase (JNK) is a member of the mitogen activated

protein kinase family and is a key intracellular signalling molecule involved in the control of cell fate. Inhibition of JNK has been reported to protect hepatotoxicity in ischemia-reperfusion model [121]. Recently knockout and knockdown approaches have provided evidence that APAP induces a prolong activation of JNK resulting into hepatocellular necrosis [122]. This study further suggested that JNK inhibition markedly protects against paracetamol induced liver injury, despite of glutathione (GSH) depletion/covalent binding. Therefore JNK inhibition might find clinical application in the group of patients that present late after overdose or in which timing of the overdose is unclear.

### Drug Induced Mitochondrial Injury

Mitochondrial DNA may be particularly vulnerable to injury and act as a sensitizer to hepatotoxicity with drugs such as valproate, possibly be mediated through effect on mitochondrial fatty acid beta oxidation [123-125]. Other studies suggest anti mitochondrial antibodies may follow the intake of iproniazid [126].

In addition, mitochondria may exhibit functional and/or acquired defects (for example infection or diabetes); leaving then susceptible to drug toxicity (aspirin, NSAIDs or reactive metabolites) although some effect of mitochondrial mutations are still unclear. Recent evidence suggests that mitochondrial injury may be progressive and a result of increased/cumulative oxidative stress [127].

## 5. CLINICAL IMPLICATIONS

### Clinical Pattern of DILI

In general, liver injury caused by drugs is known to be either Type A “dose dependent” (intrinsic toxicity) or Type B idiosyncratic [128, 129]. Perhaps with the main exception of single high dose of paracetamol-associated liver injury,

most DILI cases evaluated in clinical practice are considered as idiosyncratic [4].

As the rule, predictable reactions can be detected at the preclinical and clinical stage of drug development. In general, these reactions are dose related (intentional or accidental). Predictable reactions have short latency period usually several hours to a few days (e.g. acetaminophen or chemotherapy drugs). Although idiosyncratic allergic hepatotoxicity is considered unrelated to dose, however this reaction has been observed when drugs were given at a daily dose of 100 mg or higher, being the likelihood of hepatotoxicity greatly reduced with potent drugs and it is very rare to see an example when a drug is administered at a dose below 10 mg per day [130].

The mechanism of hepatotoxicity is poorly understood. It can be accompanied with 1) immunoallergic features such as eosinophilia, rash, antibody titer and fever having variable, usually short latency period (1-6 weeks) or 2) proceed without immunoallergic manifestations and delayed latency period (up to 1 year) [12, 13]. However, the absence of the common features of hypersensitivity does not exclude an immune mediated toxicity. These features are only present in 23 % of the patients with DILI [6]. Many independent costimulatory factors may determine idiosyncratic DILI such as environment, age, sex, infections and pharmacogenetic variation in drug metabolising polymorphisms between individuals (Table 1).

### Risk factors and DILI

#### Gender

It is generally accepted that women are more vulnerable than men to the toxic effects of drugs in the liver, however gender differences have not always become apparent when large case series were analyzed [6]. Regarding the clinicopa-

**Table 1. Reported Risk Factors in DILI**

Risk Factors	Mechanisms	Examples of Drugs
Age	Advanced age- reduced metabolic capacity, changes in hepatic blood flow, diminished immune response, decrease renal clearance, wide exposure to drugs (tendency to cholestatic type of damage) [105] Younger age- increased immunoallergic response (tendency to hepatocellular type of damage) [131] Newborns- lack of Phase I and II enzyme	Isoniazid, Halothane, Nitrofurantoin, Amoxicillin-clavulanate [131, 164,167] Valproic acid and Salicylate [164,165] Resistance to Acetaminophen hepatotoxicity. Susceptibility to Valproic acid hepatotoxicity [164-166]
Gender	Women/ unknown Men/ unknown	Diclofenac, Isoniazid, Nitrofurantoin [165, 167] Hepatic failure, Chronic autoimmune hepatitis, herbal toxicity [109, 164, 168, 169] Azathioprin [170]
Nutritional factors	Obesity- increased expression of CYP2E1 [171] Poor nutrition- glutathione depletion	Halothane, Methotrexate [165] Acetaminophen [172]
Pregnancy	Decreased synthesis of glutathione	Tetracyclin [165]
Chronic alcohol abuse	CYP2E1 induction (NAPQI formation)	Acetaminophen [173] Methotrexate, Isoniazid, Halothan, Cocain [165]
Underlying liver disease Hepatitis C, HIV	Cytokine imbalance	Anti-tuberculous drugs [174] Anti-retroviral drugs [175]
Chronic cholestatic disorders	Unknown	Rifampicin [176]

**Table 2. Reported Genetic Determinants in Drug Induced Hepatotoxicity**

Gene/Polymorphism	Description	Drugs	Chromosome
<b>EPHX1</b> Epoxide Hydrolase 1 [177, 178]	Epoxide hydrolase 1; activation and detoxification of polycyclic aromatic hydrocarbons	Phenytoin	1q42.1
<b>ARH</b> Aryl Hydrocarbon receptor [179, 180]	AHR signalling in hepatocytes is necessary to generate adaptive and toxic responses in the liver [165]	Environmental pollutants, notably polychlorinated dioxins and biphenyls benzo(a)pyrene	7p15
<b>NAT2</b> Isoniazid inactivation [182, 183]	Isoniazid hepatotoxicity is more frequent in slow inactivators (acetylators); racial variation present	Arylamine substrates (Sulfamethazine) Isoniazid Hydralazine	8p23.1-21.3
<b>CYP2C9</b> Cytochrome P450 subfamily IIC [184]	Cytochrome P450	Warfarin Phenytoin Glipizide Tolbutamide	10q24
<b>CYP2D6</b> [185, 186]	Monohydroxylation may be 100 times lower in poor metabolisers [187, 188]	Perhexilene	22q13.1
<b>CYP2C19</b> [184]	Poor metaboliser phenotype may increase susceptibility to hepatotoxicity	Mephenytoin Omeprazole Proguanil	10q24.1-3
<b>GSTP1; GST3</b> [187, 188]	Glutathione S-Transferase; catalyzes conjugation of hydrophilic and hydrophobic compounds	Felbamate Methamphetamine	11q13
<b>KRT18; KRT18</b> Cytokeratin 18 [189]	associated with liver cirrhosis; with may act as susceptibility gene for hepatotoxicity	Acetaminophen Griseofulvin	12q13
<b>UDP-Glycosyl Transferase 1: UGT1A9</b> [190]	Reversible increased serum liver transaminases	Entacapone, Tolcapone	2q37

thological expression of hepatotoxicity, the variety of chronic autoimmune hepatitis that is induced by drugs is seen almost exclusively in women. Hepatotoxicity with certain medications such as nitrofurantoin, chlorpromazine, tetracycline, halothane, and diclofenac has been reported more frequently in women [59]. Female sex along with hepatocellular liver damage and increase total bilirubin levels on admission is suggested to be a risk factor for development of fulminant liver failure [6].

### Age

Analysis of a cohort of patients with hepatotoxicity, considered all drugs collectively suggested older age to be a risk factor to develop hepatotoxicity [6]. Recently a large Spanish cohort study reported the age-related pattern of liver damage resulting from amoxicillin-clavulanate (AC) treatment. According to this study older age is related to cholestatic/mixed type of damage while younger age is associated with cytotoxic damage [131]. Hepatocellular damage in the whole population was inversely correlated with age and had the worst outcome [6].

### Alcohol

Alcohol is capable of modulating the hepatotoxic potential of other drugs through CYP induction, inhibition, or substrate competition. Alcohol seems to have a dual effect on CYP2E1. During chronic regular intake, ethanol enhances acetaminophen hepatotoxicity by inducing CYP2E1, as well as susceptibility to liver damage from isoniazid, methotrexate, halothane, and cocaine, and perhaps to other drugs that are substrates for this microsomal isoform. During

acute intake, however, substrate competition with acetaminophen occurs, actually decreasing the speed of metabolism of this drug to its toxic intermediate. However, this latter effect is partially counteracted by the ability of alcohol to slow the degradation of the CYP2E1 fraction, thus enhancing again the formation of the harmful metabolite once alcohol intake is interrupted. Alcohol also contributes to acetaminophen hepatotoxicity by the direct inhibition of glutathione synthesis and through the malnutrition that frequently accompanies chronic alcoholism [59].

### Smoking

Cigarette smoking was reported to be a risk factor for the development of hepatotoxicity [132, 133]. Cigarette smoke contains thousands of structurally diverse chemicals that possess cytotoxic, genotoxic, and tumorigenic activity. A toxic air pollutant formed by smoking such as acrolein was reported to induce hepatotoxicity through a direct mitochondrial damage [132]. Moreover, smoking may induce CYP isoform (CYP2E1) and could contribute to acetaminophen hepatotoxicity and alcohol-induced liver disease [133].

### Clinical Presentation of DILI and Treatment

At presentation, DILI may mimic all forms of acute and chronic hepatobiliary disease [134]. Therefore, the possibility of DILI should be considered in every patient with liver dysfunction and especially in older patients presenting with a non-obstructive cholestatic/mixed pattern of damage [131]. Use of non-prescription, concomitant treatment, herbal or alternative medication may be important underreported risk factors [135, 136]. Indeed, numerous herbal compounds-



**Table 3. Selected Immunological Determinants of Hepatotoxicity**

Gene/Polymorphism	Description	Drugs	Chromosome(s)
HLADRB1*15	Increased in cholestatic/mixed hepatotoxicity	Various [109]	6p21.3
HLADRB1*1501-DRB5*0101-DQB1*0602 haplotype	Increase cholestatic/mixed hepatotoxicity	Amoxicillin clavulanic acid [106]	6p21.3
HLADQB1*06	Increased in cholestatic/ mixed hepatotoxicity	Amoxicillin clavulanic acid [109]	6p21.3
HLADRB1*07 and HLADQB1*02	Protective in cholestatic/mixed hepatotoxicity	Various [109]	6p21.3
Interleukin 1 family	Initiates host response to injury by activating transcription factors, including NFkB and AP1 which effect inflammatory response	Acetaminophen [191]	2q12.1
<b>Other</b>			
TNF cytokine family	Determines severity of acetaminophen reactions; other related TNF ligands may induce apoptosis [192]	Acetaminophen [191] Cadmium [193]	3q26
Interleukin 10	Promoter linked to liver toxicity especially in alcoholics [194]	Diclofenac [29]	1q31-2
<b>NR113</b> ; (constitutive androstane CAR receptor-beta) [195]	Nuclear receptor subfamily 1 transcription factors; ligand binders; key regulator of acetaminophen metabolism and hepatotoxicity	Steroids, Thyroid hormone, Retinoic acid, Vitamin D.	
<b>Autoantibodies</b>	Antimitochondrial (M6) Anti-LKM-2 Anti-CYP1A2 Anti-CYP2E1 Antimicrosomal epoxide hydrolase Aldolase B	Iproniazid [196] Tieneilic Acid [195, 198] Dihydralazine [198] Halothane [199] Germander [200] Troglitazone [201] Disulfiram [202]	

OMIM, Online Mendelian Inheritance in Man.

<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=omim>.

including weight-loss preparations (ma-huang, hydroxycut) [137, 138], kava [139], chaparral leaf [140] amongst others have been found to induce severe liver injury. Other causes of liver dysfunction, such as hepatitis B, C, HIV, biliary tract, alcohol-induced liver disease or non-alcoholic fatty liver disease may act as contributing factors. In addition, the temporal relationship, the response to dechallenge and, in some instances, to inadvertent rechallenge are important considerations in assigning causality [18].

Finally, because of effective therapy for DILI does not exist, the most important intervention is the prompt discontinuation of the drug. Specific antidotes are available only for acetaminophen intoxication (N-acetylcystein) [141] and valproate induced mitochondrial injury (intravenous carnitin) [142]. If severe allergic reaction appears, corticosteroid could be of benefit; however no controlled trials have been performed to establish its efficacy. Ultimately, if acute hepatic failure ensues, patients may require liver-plantation.

### Clinical Significance of DILI


Individual susceptibility to idiosyncratic hepatotoxicity is determined by the interaction of multiple metabolic pathways and immunological factors that might influence immune responsiveness and tissue injury (Fig. 3). Production of reactive metabolites due to disbalance of toxification/detoxification pathways is a critical step to trigger hepatocellular apoptosis/necrosis or produce immunoallergic

hepatitis. Generally for the majority of treated patients the drug administered is entirely safe. Only few numbers of patients develop elevated level of alanine aminotransferase (ALT) and /or direct biliubin (well known markers of liver injury) [143] however rest will suffer adaptation/tolerance with continued treatment [144] as has been shown with some drugs (statins, isoniazid) [145]. Those who are unable to adapt to the injury may become susceptible to develop drug-induced liver injury or progress into severe liver toxicity.

It is important to stress that genetic studies seeking associations with diseases that do not exhibit a classical inheritance attributable to a single gene locus are subject to a variety of potential pitfalls, especially the risk of type II errors (failure to reject a false null hypothesis) if the sample size is too small, which often limits the significance of the data reported [59].

### 6. CHALLENGES FACING GENETIC ANALYSES FOR ASSOCIATION STUDIES AND WHOLE GENOME STUDIES

Association studies can generally be classified as “direct” or “indirect” approaches. Direct approaches rely on identification of functional polymorphisms of interest using bioinformatics tools. Indirect studies may identify a variant or marker that is close to the functional polymorphism in the same gene (termed linkage disequilibrium or “LD Where allelic heterogeneity is low (only one or two disease-associated alleles in each of the genes that influence risk), an



**Fig. (3).** Mechanisms underlying idiosyncratic drug-induced liver injury (DILI).

indirect approach is more efficient [146]. The “haplotype map” project initiated by the US National Institutes of Health has identified “haplotype-tagging” SNPs (International HapMap Project, <http://www.hapmap.org/>), based on African, European and Asian populations, in which 4-10 single-nucleotide polymorphisms (SNPs) in each gene are used to “tag” the haplotypes and capture most of the common variation in the gene [147]. Currently almost 6.4 million SNPs have been identified, with further detail on LD values, recombinations and hotspots for reference available from the website. Although tag SNPs can be used for several populations, this may fail to detect an association if the ADR is caused by rare haplotypes [148].

Whole genome association studies (WGA) are now possible using SNP chips such as Illumina or Affymetrix, rendering technology platforms more efficient and affordable, provided there is adequate statistical power to detect associations at stringent levels of significance that allow for multiple testing [149, 150]. One cause of spurious associations is population stratification, which can arise where populations differ in the frequency of the trait prevalence and the frequency of the polymorphism and should be adjusted for. Although technology has vastly improved in recent years; error rates are still problematic. Using the same genotyping platforms for cases and controls can help to reduce differential error rates in genotype scoring which can bias results, unless adjusted for [151].

ADRs such as DILI show complex phenotypic variation; and there are likely to be several different genetic mechanisms underlying the classification of liver injury. As DILI and other idiosyncratic adverse drug reactions are typically extremely rare, initiatives such as Spanish Registry of Hepatotoxicity, DILI network in EEUU, HepaTox and Eudragene

may be useful in providing biological collections for hypothesis testing of underlying genetic variants [152].

Determination of genes whose products are involved in the development and regulation of inflammation, apoptosis and tissue repair may yield further clues to molecular mechanism of DILI. Identification of critical proteins modified by reactive metabolites and their functional consequences represent important task for future understanding of the role of metabolic activation in DILI [8]. Determination of conventional cytotoxic marker for apoptosis (e.g. activation of caspases), cytolysis (e.g. LDH release, membrane-impermeable DNA stain), loss of critical macromolecules (ATP or glutathione (GSH), mitochondrial effects (e.g. tetrazolium salt essays, Alamar blue assay) and anti-proliferative effects (e.g. inhibition of DNA synthesis or protein synthesis) might be helpful to identify multifaceted phenomenon of DILI.

The use of “humanized” transgenic mice represents a potentially important tool for further identification of molecular mechanism of DILI. The use of metabolically-competent hepatocytes that express phase I and II and III enzymes are highly encouraged. Current advances in high-throughput technologies allow the cataloguing of genetic variants for common serious pharmacogenetic traits. Technologies such as transcriptomics, proteomics and metabolomic profiling of hepatotoxic drugs and non-hepatotoxic counterparts might result in the discovery of new biomarkers for liver toxicity [153].

#### **Identification and Nomenclature of Drug Metabolising Polymorphisms**

Classification of drug metabolising enzymes has been attempted on all members of the P450 family from whole

genome sequence data. Nelson *et al.* were the first to attempt a systematic classification of CYP450 polymorphisms following an official nomenclature proposal [155]. Further information on drug metabolising polymorphisms is available through OMIM (Online Mendelian Inheritance in Man <http://www.ncbi.nlm.nih.gov/entrez>)

### Approaches to Studying Complex Traits

Several approaches are likely to be required to study complex traits such as DILI particularly as phenotypes show considerable variation and pharmacologically relevant genes may be up and down regulated in response to other gene expression and drug administration. Furthermore projects such as HapMap that characterize genetic variation in African, European and Asian populations will require extensions to other populations including South Americans [157].

Alternative approaches to clinical pharmacogenetics include extreme discordant phenotype (EDP) methodology which studies patient pairs in drug treated populations for example comparing those who exhibit and adverse events against those who do not taking low and high extremes of drug dosage [158]. The EDP aims to correlate extreme phenotype (for example drug sensitivity) with genotype, however this is limited by the numbers identified in each group and requires prior identification of the causative genetic variant.

Ethnicity, and population stratification including admixture are also important in relation to study ADRs and methods to controls for this have been developed [159]. However drug metabolising genes may display large frequency differentials even within Europe which may act as confounders, unless adjusted for [160].

### Pharmacogenetic Testing

Clinical trials could be a potentially useful source of collecting data in drug metabolising polymorphisms in individuals; however even large clinical trials may fail to detect rare adverse events such as hepatotoxicity. Pharmacogenetic tests may be considered as a pre-treatment screening tool before prescribing medications, or amongst first degree relatives who share increased risk of pharmacogenetic traits. Screening chips for common variants are already commercially available : Amplichip CYP450 produced by Roche diagnostics and EU approved allows analysis of 29 polymorphisms and mutations for the CYP2D6 gene and 2 polymorphisms for the CYP2C19 gene, with predicted phenotype (poor, intermediate, extensive, or ultra rapid metabolizer); although current costs are high (450 euros). Rapid advances in technology are now leading the way for custom built SNPs with the potential to test thousands of multiple drug metabolising polymorphisms. Further challenges lie in the interpretation of complex pharmacogenetic data (including sensitivity, specificity and positive predictive value) in assessing an individual's risk for drug safety.

### Problems Associated with Pharmacogenetic Testing and Predicting Drug Response

More practical difficulties include selection and counselling of patients, and the increased workload and economic costs for physicians and laboratories in undertaking these tests. Transition from medical research to practical imple-

mentation is slow and ability to interpret results of genetic tests is difficult even amongst trained staff. Rare genetic variants associated with adverse drug reactions may also fail to be detected *via* haplotype strategies, or haplotype approaches may simply identify SNPs in LD with causal genetic markers. Therapeutic monitoring (for example CYP2C9 polymorphisms in the case of warfarin sensitivity) may provide a quicker method of adapting the individual's drug dose to reach the target concentrations than conventional pharmacogenetic testing [154]. Furthermore a pharmacogenetic test may have both high sensitivity and specificity yet fail in predictive value if prevalence of ADR is low.

### 7 .FUTURE PERSPECTIVES

Creation of large prospective database on DILI through collaborative multidisciplinary and multicentric networks focused on the identification of bona fida cases following the same structural report form has been the very first step to provide insights into epidemiology and pathogenesis of DILI. This has allowed creating a pharmacoepidemiological culture in the attending physicians that become more alert in the detection of DILI and consequently the recruitment of well characterised cases that would promote understanding of complex mechanism of DILI. This has been accomplished by Spanish Registry set up in 1994 [6] and in 2002 by Drug-Induced Liver Injury Network (DILIN) in USA along with collaboration of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Health (<http://diln.dcri.duke.edu/web>).

DILI in paediatric patients is an orphan field and there is obvious need to develop strategies to accomplish implementation of a specific network in this age group [161-163].

### EUDRAGENE and Hepatotoxicity

Further collection of cases of drug induced hepatotoxicity are underway with the EUDRAGENE project, funded by the European Commission 5<sup>th</sup> Framework programme. This project is establishing a freely-shared case-control collection of DNA samples, as a multi-centre European collaboration. A multi-centre collaboration is required as no single centre is able to generate enough cases within a reasonable period of time. This will act as a resource for studying genetic predictors of adverse drug reactions, using the existing system for spontaneous reporting of suspected adverse drug reactions to national or regional pharmacovigilance centres. Currently this project is collecting clinical data and DNA on all identified cases of drug induced hepatotoxicity as defined by CIOMS international standards [146] from several European centres. Classification of liver injury will collect data on laboratory tests and allow classification into hepatocellular; cholestatic and mixed categories, and severity of hepatotoxicity based on ratio of enzymatic abnormalities to standardised normal range values. Analyses of the determinants of hepatotoxicity will be undertaken based on drug class and hepatotoxicity classification. Further detail on the EUDRAGENE project is given from the website [146].

### REFERENCES

- [1] Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. *N Engl J Med* 1998; 338: 916-7.
- [2] Lee WM. Acute liver failure in the United States. *Semin Liver Dis* 2003; 23: 217-26.

- [3] Temple R. Policy developments in regulatory approval. *Stat Med* 2002; 21: 2939-48.
- [4] Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. *Drug Metab Rev* 2004; 36: 301-12.
- [5] Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. *J Hepatol* 2002; 37: 592-600.
- [6] Andrade RJ, Lucena MI, Fernandez MC, *et al.* Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology* 2005; 129: 512-21.
- [7] Larrey D. Drug-induced liver diseases. *J Hepatol* 2000; 32: 77-88.
- [8] Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. *Annu Rev Pharmacol Toxicol* 2005; 45: 177-202.
- [9] Sgro C, Clinard F, Ouazir K, *et al.* Incidence of drug-induced hepatic injuries: a French population-based study. *Hepatology* 2002; 36: 451-5.
- [10] Meier Y, Cavallaro M, Roos M, *et al.* Incidence of drug-induced liver injury in medical inpatients. *Eur J Clin Pharmacol* 2005; 61: 135-43.
- [11] Maddrey WC. Drug-induced hepatotoxicity. *J Clin Gastroenterol* 2005; 39: 83-89.
- [12] Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. *Semin Liver Dis* 2002; 22: 145-55.
- [13] Egger T, Dormann H, Ahne G *et al.* Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study. *Drugs Aging* 2005; 22: 265-72.
- [14] Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. *Clin Pharmacokinet* 2005; 44: 1209-25.
- [15] Larrey D. Hepatotoxicity of herbal remedies. *J Hepatol* 1997; 26 Suppl 1: 47-51.
- [16] Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. *J Hepatol* 1994; 21: 1075-9.
- [17] Seybold U, Landauer N, Hillebrand S, Goebel FD. Senna-induced hepatitis in a poor metabolizer. *Ann Intern Med* 2004; 141: 650-1.
- [18] Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. *Expert Opin Drug Saf* 2004; 3: 329-44.
- [19] Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *Br J Clin Pharmacol* 1998; 45: 525-38.
- [20] Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. *Br J Clin Pharmacol* 2001; 52: 447-50.
- [21] De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. *Mol Pharmacol* 1994; 46: 594-8.
- [22] Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. *Clin Pharmacol Ther* 2005; 77: 1-16.
- [23] Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. *J Hepatol* 1997; 26 Suppl 2: 12-21.
- [24] Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M. Leflunomide-induced acute hepatitis. *Dig Liver Dis* 2004; 36: 82-4.
- [25] Morin S, Lorient MA, Poirier JM *et al.* Is diclofenac a valuable CYP2C9 probe in humans? *Eur J Clin Pharmacol* 2001; 56: 793-7.
- [26] Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics* 2000; 10: 511-8.
- [27] Yasar U, Eliasson E, Forslund-Bergengren C *et al.* The role of CYP2C9 genotype in the metabolism of diclofenac *in vivo* and *in vitro*. *Eur J Clin Pharmacol* 2001; 57: 729-35.
- [28] Bort R, Mace K, Boobis A *et al.* Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. *Biochem Pharmacol* 1999; 58: 787-96.
- [29] Aithal GP, Ramsay L, Daly AK *et al.* Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. *Hepatology* 2004; 39: 1430-40.
- [30] Kirchheiner J, Kudlicz D, Meisel C *et al.* Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. *Clin Pharmacol Ther* 2003; 74: 186-94.
- [31] Goldstein JA, Faletto MB, Romkes-Sparks M *et al.* Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. *Biochemistry* 1994; 33: 1743-52.
- [32] Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. *Pharmacogenetics* 1992; 2: 25-31.
- [33] Baumann P. Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test. *Encephale* 1986; 12: 143-8.
- [34] Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. *Clin Pharmacol Ther* 1989; 45: 72-9.
- [35] Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. *Clin Pharmacokinet* 1995; 29: 192-209.
- [36] Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. *Br J Clin Pharmacol* 2003; 56: 653-7.
- [37] Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. *Pharmacogenetics* 1995; 5: 358-63.
- [38] Brosen K, de Morais SM, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. *Pharmacogenetics* 1995; 5: 312-7.
- [39] Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. *J Hepatol* 1994; 21: 1075-9.
- [40] Ketevan Pachkoria, M Isabel Lucena, Francisco Ruiz-Cabello, Esperanza Crespo, Maria R Cabello, Raúl J Andrade. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). *BJP* (accepted manuscript number: 2006BJP0853FP)
- [41] Dorado P, Berecz R, Caceres MC, Gonzalez I, Cobaleda J, Llerena A. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. *Clin Chem Lab Med* 2005; 43: 275-9.
- [42] Marez D, Legrand M, Sabbagh N *et al.* Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. *Pharmacogenetics* 1997; 7: 193-202.
- [43] Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. *Br J Clin Pharmacol* 2002; 53: 111-22.
- [44] Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. *Gut* 1984; 25: 1057-64.
- [45] Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, Elias E. A proposed mechanism for chlorpromazine jaundice--defective hepatic sulphoxidation combined with rapid hydroxylation. *J Hepatol* 1988; 7: 72-8.
- [46] Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. *Ther Drug Monit* 2004; 26: 127-31.
- [47] Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. *Clin Pharmacokinet* 1998; 34: 281-302.
- [48] Otani K, Kaneko S, Tasaki H, Fukushima Y. Hepatic injury caused by mianserin. *Bmj* 1989; 299: 519.

- [49] Yasui N, Otani K, Kaneko S *et al.* Inhibition of trazodone metabolism by thioridazine in humans. *Ther Drug Monit* 1995; 17: 333-5.
- [50] Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. *Bmj* 1994; 309: 378.
- [51] Inoue K, Inazawa J, Nakagawa H, *et al.* Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. *Jpn J Hum Genet.* 1992; 37: 133-138.
- [52] Nelson DR, Koymans L, Kamataki T, *et al.* P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics.* 1996; 6: 1-42. Review.
- [53] Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. *Drug Metab Dispos.* 2001; 29: 268-273.
- [54] Klees TM, Sheffels P, Thummel KE, Kharasch ED. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. *Anesthesiology.* 2005; 102: 550-556.
- [55] Staudinger JL, Goodwin B, Jones SA, *et al.* The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. *Proc Natl Acad Sci U S A.* 2001; 98: 3369-3374.
- [56] Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. *Pharmacogenetics.* 2004; 14: 635-645.
- [57] Kostrubsky VE, Szakacs JG, Jeffery EH, *et al.* Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. *Toxicol Appl Pharmacol.* 1997; 143: 315-23.
- [58] Lakehal F, Dansette PM, Becquemont L *et al.* Indirect cytotoxicity of flucloxacillin toward human biliary epithelium *via* metabolite formation in hepatocytes. *Chem Res Toxicol* 2001; 14: 694-701.
- [59] Andrade RJ, Salmeron FJ, Lucena MI. Drug Hepatotoxicity. En: *The Clinician's Guide to Liver Disease*, Reddy KR & Faust T eds. Slack Incorporated, NJ, USA. 2005
- [60] Kassahun K, Pearson PG, Tang W, *et al.* Studies on the metabolism of troglitazone to reactive intermediates *in vitro* and *in vivo*. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. *Chem Res Toxicol.* 200; 14: 62-70.
- [61] Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. *Ann Pharmacother.* 2006; 40: 753-757.
- [62] Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, Garcia-Munoz B. Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. *World J Gastroenterol.* 2006; 12: 5244-5246.
- [63] Gaikovitch EA, Cascorbi I, Mrozkiewicz PM *et al.* Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. *Eur J Clin Pharmacol* 2003; 59: 303-12.
- [64] Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. *Curr Drug Targets Immune Endocr Metabol Disord.* 2005; 5: 289-303.
- [65] Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. *Eur J Clin Pharmacol* 2006; 62: 355-359.
- [66] Gross M, Kruiesselbrink T, Anderson K *et al.* Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. *Cancer Epidemiol Biomarkers Prev* 1999; 8: 683-92.
- [67] Evans DA. N-acetyltransferase. *Pharmacol Ther* 1989; 42: 157-234.
- [68] Weber WW, Hein DW. N-acetylation pharmacogenetics. *Pharmacol Rev* 1985; 37: 25-79.
- [69] Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. *Pharmacogenetics* 1996 6: 423-8.
- [70] Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. *Pharmacogenetics* 1994; 4: 125-34.
- [71] Xie HG, Xu ZH, Ou-Yang DS *et al.* Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. *Pharmacogenetics* 1997; 7: 503-14.
- [72] Huang YS, Chern HD, Su WJ *et al.* Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. *Hepatology* 2002; 35: 883-9.
- [73] Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. *Clin Pharmacol Ther* 1976; 19: 610-25.
- [74] Lauterburg BH, Smith CV, Todd EL, Mitchell JR. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. *J Pharmacol Exp Ther* 1985; 235: 566-70.
- [75] Mitchell JR, Thorgeirsson UP, Black M *et al.* Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazino metabolites. *Clin Pharmacol Ther* 1975; 18: 70-9.
- [76] Mitchell JR, Potter WZ. Drug metabolism in the production of liver injury. *Med Clin North Am* 1975; 59: 877-85.
- [77] Olomu AB, Vickers CR, Waring RH *et al.* High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. *N Engl J Med* 1988; 318: 1089-92.
- [78] Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. *Lancet* 2000; 356: 1587-1591.
- [79] Kaplowitz N. Idiosyncratic drug hepatotoxicity. *Nat Rev Drug Discov* 2005; 4: 489-99.
- [80] Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, Groothuis GM. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. *Biochim Biophys Acta* 1995; 1241: 215-268.
- [81] Smith AJ, van Helvoort A, van Meer G *et al.* MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. *J Biol Chem* 2000; 275: 23530-9.
- [82] Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. *Biochim Biophys Acta* 1999; 1461: 377-94.
- [83] Cole SP, Bhardwaj G, Gerlach JH *et al.* Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* 1992; 258: 1650-4.
- [84] Grant CE, Kurz EU, Cole SP, Deeley RG. Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. *Genomics* 1997; 45: 368-78.
- [85] Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. *Gastroenterology* 1999; 117: 653-60.
- [86] Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. *J Cell Biol* 1995; 131: 137-50.
- [87] Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. *Mol Pharmacol* 1999; 55: 929-37.
- [88] Awasthi CW, Awasthi S, Zimniak P. Multiple transport protein involved in the detoxification of endo- and xenobiotics. *Frontiers in Bioscience* 1997; 15: 427-437.
- [89] Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D. MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. *Am J Physiol Gastrointest Liver Physiol* 2000; 278: G522-31.
- [90] Bolder U, Trang NV, Hagey LR *et al.* Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. *Gastroenterology* 1999; 117: 962-71.
- [91] Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. *Chem Res Toxicol* 2001; 14: 175-81.
- [92] Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP. MRP2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. *Carcinogenesis* 2001; 22: 805-11.
- [93] Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. *N Engl J Med* 1998; 339: 1217-27.
- [94] Dixon PH, Weerasekera N, Linton KJ *et al.* Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of preg-

- nancy: evidence for a defect in protein trafficking. *Hum Mol Genet* 2000; 9: 1209-17.
- [95] Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. *Lancet* 1999; 353: 210-1.
- [96] de Vree JM, Jacquemin E, Sturm E *et al.* Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. *Proc Natl Acad Sci U S A* 1998; 95: 282-7.
- [97] Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. *Gastroenterology* 2001; 120: 1459-67.
- [98] Njoku DB, Greenberg RS, Bourdi M *et al.* Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. *Anesth Analg* 2002; 94: 243-9.
- [99] Aithal GP. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. *Expert Opin Drug Saf* 2004; 3: 519-23.
- [100] Kaplowitz N. Drug-induced liver injury. *Clin Infect Dis* 2004; 38 Suppl 2: S44-8.
- [101] Hautekeete ML. Hepatotoxicity of antibiotics. *Acta Gastroenterol Belg* 1995; 58: 290-6.
- [102] Bourdi M, Masubuchi Y, Reilly TP, *et al.* Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. *Hepatology* 2002; 35: 289-298.
- [103] Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. *Biochem Biophys Res Commun* 2003; 304: 207-12.
- [104] Grypioti AD. Liver Oxidant Stress Induced By Paracetamol Overdose. *The Internet Journal of Pharmacology* 2006; 4: 1531-2976.
- [105] Lucena MI, Pachkoria K, Ruiz-Cabello F, *et al.* Lack of association of interleukin-10 promoter gene variants in drug-induced idiosyncratic liver injury (DILI) in a Spanish population. *Basic and Clinical Pharmacology & Toxicology*. 20<sup>th</sup> Congress of the Spanish Clinical Pharmacology Society Puerto de la Cruz (Tenerife), Spain. Abstract.
- [106] Hautekeete ML, Horsmans Y, Van Waeyenberge C *et al.* HLA association of amoxicillin-clavulanate--induced hepatitis. *Gastroenterology* 1999; 117: 1181-6.
- [107] Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. *Am J Respir Crit Care Med* 2002; 166: 916-9.
- [108] Berson A, Freneaux E, Larrey D *et al.* Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. *J Hepatol* 1994; 20: 336-42.
- [109] Andrade RJ, Lucena MI, Alonso A *et al.* HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. *Hepatology* 2004; 39: 1603-12.
- [110] Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. *Gastroenterology* 2005; 129: 351-60.
- [111] Ding WX, Ni HM, DiFrancesca D, Stolz DB, Yin XM. Bid-dependent generation of oxygen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. *Hepatology* 2004; 40: 403-13.
- [112] Jiang X, Wang X. Cytochrome C-mediated apoptosis. *Annu Rev Biochem* 2004; 73: 87-106.
- [113] Herman B, Nieminen AL, Gores GJ, Lemasters JJ. Irreversible injury in anoxic hepatocytes precipitated by an abrupt increase in plasma membrane permeability. *Faseb J* 1988; 2: 146-51.
- [114] Gores GJ, Herman B, Lemasters JJ. Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury. *Hepatology* 1990; 11: 690-8.
- [115] Nishimura Y, Romer LH, Lemasters JJ. Mitochondrial dysfunction and cytoskeletal disruption during chemical hypoxia to cultured rat hepatic sinusoidal endothelial cells: the pH paradox and cytoprotection by glucose, acidotic pH, and glycine. *Hepatology* 1998; 27: 1039-49.
- [116] Kaplowitz N. Cell death at the millennium. Implications for liver diseases. *Clin Liver Dis* 2000; 4: 1-23, v.
- [117] Wei MC, Zong WX, Cheng EH *et al.* Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* 2001; 292: 727-30.
- [118] Hatano E, Bradham CA, Stark A, Iimuro Y, Lemasters JJ, Brenner DA. The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. *J Biol Chem* 2000; 275: 11814-23.
- [119] Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis *via* two sequential signaling complexes. *Cell* 2003; 114: 181-90.
- [120] Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. *Cell Death Differ* 2003; 10: 26-35.
- [121] Uehara T, Bennett B, Sakata ST, *et al.* JNK mediates hepatic ischemia reperfusion injury. *J Hepatol*. 2005; 42: 850-859.
- [122] Kaplowitz N. Liver biology and pathobiology. *Hepatology*. 2006; 43: 235-238. Review.
- [123] Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. *Neuromuscul Disord* 2001; 11: 757-759.
- [124] Krahenbuhl S, Brandner S, Kleinle S, Liechti S, Straumann D. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. *Liver* 2000; 20: 346-8.
- [125] McLaughlin DB, Eadie MJ, Parker-Scott SL *et al.* Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. *Epilepsy Res* 2000; 41: 259-68.
- [126] Pons C, Dansette PM, Gregeois J, Homberg JC, Billett EE, Mansuy D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. *Biochem Biophys Res Commun* 1996 ; 218: 118-24.
- [127] Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? *Curr Opin Infect Dis* 2000; 13: 5-11.
- [128] Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. *Textbook of adverse drug reactions*. Oxford: Oxford University Press, 1977: 10.
- [129] Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. *Chem Res Toxicol* 1998; 11: 969-88.
- [130] Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. *Crit Rev Toxicol*. 2005; 35: 325-361. Review.
- [131] Lucena MI, Andrade RJ, Fernandez MC, *et al.* Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. *Hepatology*. 2006; 44: 850-856.
- [132] Sun L, Luo C, Long J, Wei D, Liu J. Acrolein is a mitochondrial toxin: effects on respiratory function and enzyme activities in isolated rat liver mitochondria. *Mitochondrion*. 2006; 6: 136-142.
- [133] Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. *Clin Pharmacol Ther*. 2003; 74: 468-474.
- [134] Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. *Drug Saf* 2001; 24: 483-90.
- [135] Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. *Semin Liver Dis* 2002; 22: 169-83.
- [136] Favreau JT, Ryu ML, Braunstein G *et al.* Severe hepatotoxicity associated with the dietary supplement LipoKinetix. *Ann Intern Med* 2002; 136: 590-5.
- [137] Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. *Am J Gastroenterol* 1996; 91: 1436-8.
- [138] Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. *Ann Intern Med* 2005; 142: 477-8.
- [139] Humberston CL, Akhtar J, Krenzelo EP. Acute hepatitis induced by kava kava. *J Toxicol Clin Toxicol* 2003; 41: 109-13.
- [140] Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. *Am J Gastroenterol* 1995; 90: 831-3.
- [141] Polson J, Lee WM. AASLD position paper: the management of acute liver failure. *Hepatology* 2005; 41: 1179-97.

- [142] Bohan TP, Helton E, McDonald I *et al.* Effect of L-carnitine treatment for valproate-induced hepatotoxicity. *Neurology* 2001; 56: 1405-9.
- [143] Black M. Diagnostic methods in liver diseases. *Med Clin North Am.* 1975 Jul; 59(4): 1015-23.
- [144] Watkins PB. Idiosyncratic liver injury: challenges and approaches. *Toxicol Pathol.* 2005; 33: 1-5.
- [145] Lucena MI, Andrade RJ. Increasing the detection of hepatotoxic response in clinical practice: a quality commitment. *Rev Esp Enferm Dig.* 2005; 97: 145-153
- [146] Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. *Pharmacogenomics* 2006; 7: 633-638.
- [147] Johnson GC, Esposito L, Barratt BJ *et al.* Haplotype tagging for the identification of common disease genes. *Nat Genet* 2001; 29(2): 233-7.
- [148] de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. *Nat Genet* 2005; 37(11): 1217-23.
- [149] Davey SG, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR. Genetic epidemiology and public health: hope, hype, and future prospects. *Lancet* 2005; 22; 366(9495): 1484-98.
- [150] Hattersley AT, McCarthy MI. What makes a good genetic association study? *Lancet* 2005; 366(9493): 1315-23.
- [151] Clayton DG, Walker NM, Smyth DJ *et al.* Population structure, differential bias and genomic control in a large-scale, case-control association study. *Nat Genet* 2005; 37(11): 1243-6.
- [152] Lash LH, Hines RN, Gonzalez FJ, Zacharewski TR, Rothstein MA. Genetics and susceptibility to toxic chemicals: do you (or should you) know your genetic profile? *J Pharmacol Exp Ther* 2003 May; 305(2): 403-9.
- [153] Welch KD, Reilly TP, Bourdi M *et al.* Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. *Chem Res Toxicol* 2006; 19: 223-33.
- [154] Becquemont L. Clinical relevance of pharmacogenetics 35: 4 277-85 2003.
- [155] Nelson DR, Strobel HW. Evolution of Cytochrome P-450 Proteins *Molec. Biol.* 1987; 6: 572-593
- [156] Nebert DW, Adesnik M, Coon MJ, *et al.* The P450 gene superfamily: Recommended nomenclature. *DNA* 1987; 6: 1-11
- [157] Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. *Eur J Pharmacol* 2004; 500: 267-280
- [158] Nebert DW. "Extreme discordant phenotype" methodology: an intuitive approach to clinical pharmacogenetics. *Eur J Pharmacol* 2000; 410: 107-120
- [159] Hoggart, C. J. *et al.* Control of confounding of genetic associations in stratified populations. *Am. J Hum. Genet.* 2003; 72: 1492-1504
- [160] Campbell, C. D. *et al.* Demonstrating stratification in a European American population. *Nat Genet.* 2005; 37: 868-872
- [161] Hoofnagle JH. Drug-induced liver injury network (DILIN). *Hepatology* 2004; 40: 773.
- [162] Peire MA, Lucena MI, Ruiz-Extremera A, Jara P, Romero-Gonzalez J, Andrade RJ. Drug-induced hepatotoxicity in children. Where we are and where we are going. *An Esp Pediatr* 2002; 56: 434-442.
- [163] Squires RH Jr, Shneider BL, Bucuvalas J, *et al.* Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. *J Pediatr.* 2006; 148: 652-658.
- [164] Zimmerman, H. Drug-induced liver disease. In: Schiff, E., Sorrell, M., Maddrey, W. Schiff's Diseases of Liver. 8th ed. Philadelphia, PA: Lippincott-Raven Publishers. 1999; 973-1064.
- [165] Farrell GC. Drug induced liver disease. 1994: London: Churchill-Livingstone.
- [166] Pineiro-Carrero VM, Pineiro EO. Liver 10.1542/peds.113.4.S1.1097. *Pediatrics* 2004; 113(4): 1097-1106.
- [167] Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. *Arch Intern Med* 1996; 156: 1327-32.
- [168] Larrey D. Hepatotoxicity: also, phytotherapy. *Gastroenterol Clin Biol* 1992; 16: 913-5.
- [169] Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. *Liver Transpl* 2004; 10: 1018-23.
- [170] de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. *Neth J Med* 2005; 63: 444-6.
- [171] Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. *Hepatology* 2001; 33: 1009-13.
- [172] Patel KP. Drug-related hepatotoxicity. *N Engl J Med* 2006; 354: 2191-3; author reply 2191-3
- [173] Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. *Cell Biol Toxicol* 1999; 1 5: 367-73.
- [174] Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. *Expert Opin Drug Saf* 2006; 5: 231-49.
- [175] Krahenbuhl S. Mitochondria: important target for drug toxicity? *J Hepatol* 2001; 34: 334-6.
- [176] Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. *Indian J Exp Biol* 2003; 41: 1226-32.
- [177] Jackson MR, Craft JA, Burchell B. Nucleotide and deduced amino acid sequence of human liver microsomal epoxide hydrolase. *Nucleic Acids Res* 1987; 15: 7188.
- [178] Hartsfield JK, Jr., Sutcliffe MJ, Everett ET, Hassett C, Omiecinski CJ, Saari JA. Assignment1 of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization. *Cytogenet Cell Genet* 1998; 83: 44-45.
- [179] Ema M, Matsushita N, Sogawa K *et al.* Human arylhydrocarbon receptor: functional expression and chromosomal assignment to 7p21. *J Biochem (Tokyo)* 1994; 116: 845-851.
- [180] Le Beau MM, Carver LA, Espinosa R, III, Schmidt JV, Bradfield CA. Chromosomal localization of the human AHR locus encoding the structural gene for the Ah receptor to 7p21-->p15. *Cytogenet Cell Genet* 1994; 66: 172-176.
- [181] Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. *Proc Natl Acad Sci U S A* 2005; 102: 17858-17863.
- [182] Blum M, Heim M, Meyer UA. Nucleotide sequence of rabbit NAT2 encoding polymorphic liver arylamine N-acetyltransferase (NAT). *Nucleic Acids Res* 1990; 18: 5295.
- [183] Hickman D, Risch A, Buckle V *et al.* Chromosomal localization of human genes for arylamine N-acetyltransferase. *Biochem J* 1994; 297 ( Pt 3): 441-445.
- [184] Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. *Genomics* 1995; 28: 328-332.
- [185] Barclay ML, Sawyers SM, Begg EJ, *et al.* Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. *Pharmacogenetics* 2003; 13: 627-632.
- [186] Gough AC, Smith CA, Howell SM, Wolf CR, Bryant SP, Spurr NK. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. *Genomics* 1993; 15: 430-432.
- [187] Silberstein DL, Shows TB. Gene for glutathione S-transferase-1 (GST1) is on human chromosome 11. *Somatic Cell Genet* 1982; 8: 667-675.
- [188] Suzuki T, Board P. Glutathione-S-transferase gene mapped to chromosome 11 is GST3 not GST1. *Somat Cell Mol Genet* 1984; 10: 319-320.
- [189] Yoon SJ, LeBlanc-Straceski J, Ward D, Krauter K, Kucherlapati R. Organization of the human keratin type II gene cluster at 12q13. *Genomics* 1994; 24: 502-508.
- [190] Harding D, Jeremiah SJ, Povey S, Burchell B. Chromosomal mapping of a human phenol UDP-glucuronosyltransferase, GNT1. *Ann Hum Genet* 1990; 54 ( Pt 1): 17-21.
- [191] Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. *Toxicol Appl Pharmacol* 1995; 133: 43-52.
- [192] Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *J Biol Chem* 1996; 271: 12687-12690.
- [193] Kayama F, Yoshida T, Elwell MR, Luster MI. Role of tumor necrosis factor-alpha in cadmium-induced hepatotoxicity. *Toxicol Appl Pharmacol* 1995; 131: 224-234.

- [194] Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. *Gut* 2000; 46: 540-545.
- [195] Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, Moore DD. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. *Mol Cell Biol* 1994; 14: 1544-1552.
- [196] Danan G, Homberg JC, Bernuau J, Roche-Sicot J, Pessayre D. Iproniazid-induced hepatitis. The diagnostic value of a new anti-mitochondrial antibody anti-M6. *Gastroenterol Clin Biol* 1983; 7: 529-532.
- [197] Neuberger J, Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. *Gut* 1989; 30: 515-519.
- [198] Lecoeur S, Bonierbale E, Challine D *et al.* Specificity of *in vitro* covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. *Chem Res Toxicol* 1994; 7: 434-442.
- [199] Gut J, Christen U, Frey N, Koch V, Stoffler D. Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. *Toxicology* 1995; 97: 199-224.
- [200] De B, V, Moulis C, Maurice M *et al.* Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. *Mol Pharmacol* 2000; 58: 542-551.
- [201] Maniratanachote R, Shibata A, Kaneko S *et al.* Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. *Toxicology* 2005; 216: 15-23.
- [202] Eliasson E, Stal P, Oksanen A, Lytton S. Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis. *J Hepatol* 1998; 29: 819-825.

---

Received: July 12, 2006

Revised: October 6, 2006

Accepted: December 7, 2006